Clinical impact and cost-effectiveness of updated 2023/24 COVID-19 mRNA vaccination in high-risk populations in the United States DOI
Keya Joshi, Mariia Dronova,

Ewelina Paterak

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 15, 2024

Abstract Introduction In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. Methods A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States. Results Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834) CKD (13,558) also provided net cost savings $399M–2,129M (healthcare payer) $457M–2,531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10–$2.60 gain every $1 invested). Healthcare a relative 10% increase ($439M–$2,342M), from meeting US 2030 targets 70% ($1,096M–$5,707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6,241), (1,979), (942) Pfizer/BioNTech’s vaccine, healthcare payer societal savings, making it dominant strategy. per patient vaccinated were $31-59, robust sensitivity/scenario analyses. Conclusions Updated provide significant health benefits through prevention populations, cost-savings payers society, Increasing low cost-saving while preventing many more infections these populations. Key Summary Points Why carry out this study? US, high COVID-19, are CDC recommends an 2024/25 everyone aged >6 months. objective estimate cost-effectiveness conditions, vaccination, What learned mRNA It gains Pfizer/BioNTech, For spent $1.10–$2.60 $31-59 Moderna’s prevented deaths, potential financial greater rates.

Язык: Английский

Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults DOI
Ekkehard Beck,

Mihaela Georgieva,

Wei-Jhih Wang

и другие.

Current Medical Research and Opinion, Год журнала: 2025, Номер unknown, С. 1 - 21

Опубликована: Фев. 20, 2025

COVID-19 continues to pose a significant health burden, particularly among older adults. mRNA-1283 is next-generation mRNA vaccine developed enhance immune response. Findings from the Phase 3 NextCOVE trial comparing bivalent versions of mRNA-1273 and vaccines have recently become available. However, there are no head-to-head trials BNT162b2 vaccine. To indirectly compare effectiveness against symptomatic adults in U.S. A targeted literature review was conducted identify relevant studies vaccines. real-world evidence (RWE) study by Kopel et al. (2023) assessing relative (rVE) vs. BNT162b2, selected for an indirect treatment comparison (ITC) using Bucher method. Analyses were stratified age group, sensitivity analyses alternative outcome definitions. Despite differences between study, comparability assessments supported robust ITC. Among participants ≥18 years age, rVE 15.3% (95% CI: 4.7-24.8%, p = 0.006). For ≥65 22.8% 3.7-38.1%, 0.022). Sensitivity with definitions these estimates. This analysis provides consistent statistically indicating more effective preventing than largest effect individuals aged ≥65. Consistent results across underscore robustness findings, offering important inform vaccination decisions policymakers, providers, payers.

Язык: Английский

Процитировано

0
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France DOI Creative Commons
Amy Lee, Benjamin Davido, Ekkehard Beck

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)

Опубликована: Ноя. 14, 2024

An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 in Fall 2023 Spring 2024 France. The number symptomatic SARS-CoV-2 infections, hospitalizations or deaths due COVID-19, long COVID cases, costs quality-adjusted life (QALYs) were estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) based on real-world data from original BA.4/5 vaccines, suggesting higher protection against infection hospitalization vaccines. VE estimates combined incidence probability severe outcomes. Uncertainty surrounding VE, coverage, incidence, mortality rates, QALYs evaluated sensitivity analyses. In an ideal situation where 100% coverage is achieved, predicted prevent additional 3,882 357 hospitalizations, 81 deaths, 326 cases when compared 230,000 IC individuals. This translates €10.1 million cost-savings societal perspective 645 gained. Results consistent across analyses most sensitive variations coverage. These findings highlight importance increasing ability induce levels formulations this vulnerable population.

Язык: Английский

Процитировано

0
Clinical impact and cost-effectiveness of updated 2023/24 COVID-19 mRNA vaccination in high-risk populations in the United States DOI
Keya Joshi, Mariia Dronova,

Ewelina Paterak

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 15, 2024

Abstract Introduction In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. Methods A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States. Results Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834) CKD (13,558) also provided net cost savings $399M–2,129M (healthcare payer) $457M–2,531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10–$2.60 gain every $1 invested). Healthcare a relative 10% increase ($439M–$2,342M), from meeting US 2030 targets 70% ($1,096M–$5,707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6,241), (1,979), (942) Pfizer/BioNTech’s vaccine, healthcare payer societal savings, making it dominant strategy. per patient vaccinated were $31-59, robust sensitivity/scenario analyses. Conclusions Updated provide significant health benefits through prevention populations, cost-savings payers society, Increasing low cost-saving while preventing many more infections these populations. Key Summary Points Why carry out this study? US, high COVID-19, are CDC recommends an 2024/25 everyone aged >6 months. objective estimate cost-effectiveness conditions, vaccination, What learned mRNA It gains Pfizer/BioNTech, For spent $1.10–$2.60 $31-59 Moderna’s prevented deaths, potential financial greater rates.

Язык: Английский

Процитировано

0